Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1998 2
1999 7
2000 7
2001 4
2002 2
2004 2
2005 2
2006 2
2007 2
2008 3
2009 3
2010 4
2011 2
2012 3
2013 4
2014 4
2015 6
2016 3
2017 4
2018 3
2019 4
2020 4
2021 6
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
Bianchi M, Reichen C, Croset A, Fischer S, Eggenschwiler A, Grübler Y, Marpakwar R, Looser T, Spitzli P, Herzog C, Villemagne D, Schiegg D, Abduli L, Iss C, Neculcea A, Franchini M, Lekishvili T, Ragusa S, Zitt C, Kaufmann Y, Auge A, Hänggi M, Ali W, Frasconi TM, Wullschleger S, Schlegel I, Matzner M, Lüthi U, Schlereth B, Dawson KM, Kirkin V, Ochsenbein AF, Grimm S, Reschke N, Riether C, Steiner D, Leupin N, Goubier A. Bianchi M, et al. Among authors: ochsenbein af. Cancer Immunol Res. 2024 Jul 2;12(7):921-943. doi: 10.1158/2326-6066.CIR-23-0692. Cancer Immunol Res. 2024. PMID: 38683145 Free PMC article.
Author Correction: Tumour mutations in long noncoding RNAs enhance cell fitness.
Esposito R, Lanzós A, Uroda T, Ramnarayanan S, Büchi I, Polidori T, Guillen-Ramirez H, Mihaljevic A, Merlin BM, Mela L, Zoni E, Hovhannisyan L, McCluggage F, Medo M, Basile G, Meise DF, Zwyssig S, Wenger C, Schwarz K, Vancura A, Bosch-Guiteras N, Andrades Á, Tham AM, Roemmele M, Medina PP, Ochsenbein AF, Riether C, Kruithof-de Julio M, Zimmer Y, Medová M, Stroka D, Fox A, Johnson R. Esposito R, et al. Among authors: ochsenbein af. Nat Commun. 2023 Sep 6;14(1):5463. doi: 10.1038/s41467-023-41288-5. Nat Commun. 2023. PMID: 37673946 Free PMC article. No abstract available.
Tumour mutations in long noncoding RNAs enhance cell fitness.
Esposito R, Lanzós A, Uroda T, Ramnarayanan S, Büchi I, Polidori T, Guillen-Ramirez H, Mihaljevic A, Merlin BM, Mela L, Zoni E, Hovhannisyan L, McCluggage F, Medo M, Basile G, Meise DF, Zwyssig S, Wenger C, Schwarz K, Vancura A, Bosch-Guiteras N, Andrades Á, Tham AM, Roemmele M, Medina PP, Ochsenbein AF, Riether C, Kruithof-de Julio M, Zimmer Y, Medová M, Stroka D, Fox A, Johnson R. Esposito R, et al. Among authors: ochsenbein af. Nat Commun. 2023 Jun 8;14(1):3342. doi: 10.1038/s41467-023-39160-7. Nat Commun. 2023. PMID: 37291246 Free PMC article.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T, Vey N, Adès L, Bacher U, Bargetzi M, Fung S, Gaidano G, Gandini D, Hultberg A, Johnson A, Ma X, Müller R, Nottage K, Papayannidis C, Recher C, Riether C, Shah P, Tryon J, Xiu L, Ochsenbein AF. Pabst T, et al. Among authors: ochsenbein af. Haematologica. 2023 Jul 1;108(7):1793-1802. doi: 10.3324/haematol.2022.281563. Haematologica. 2023. PMID: 36779592 Free PMC article. Clinical Trial.
Multi-hallmark long noncoding RNA maps reveal non-small cell lung cancer vulnerabilities.
Esposito R, Polidori T, Meise DF, Pulido-Quetglas C, Chouvardas P, Forster S, Schaerer P, Kobel A, Schlatter J, Kerkhof E, Roemmele M, Rice ES, Zhu L, Lanzós A, Guillen-Ramirez HA, Basile G, Carrozzo I, Vancura A, Ullrich S, Andrades A, Harvey D, Medina PP, Ma PC, Haefliger S, Wang X, Martinez I, Ochsenbein AF, Riether C, Johnson R. Esposito R, et al. Among authors: ochsenbein af. Cell Genom. 2022 Aug 22;2(9):100171. doi: 10.1016/j.xgen.2022.100171. eCollection 2022 Sep 14. Cell Genom. 2022. PMID: 36778670 Free PMC article.
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.
Yang H, Gao Y, Xu D, Xu K, Liang SQ, Yang Z, Scherz A, Hall SRR, Forster S, Berezowska S, Yao F, Ochsenbein AF, Marti TM, Kocher GJ, Schmid RA, Dorn P, Peng RW. Yang H, et al. Among authors: ochsenbein af. Cell Death Discov. 2023 Feb 10;9(1):55. doi: 10.1038/s41420-023-01307-2. Cell Death Discov. 2023. PMID: 36765038 Free PMC article.
Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities.
Haas Q, Markov N, Muerner L, Rubino V, Benjak A, Haubitz M, Baerlocher GM, Ng CKY, Münz C, Riether C, Ochsenbein AF, Simon HU, von Gunten S. Haas Q, et al. Among authors: ochsenbein af. Front Immunol. 2022 Sep 23;13:996746. doi: 10.3389/fimmu.2022.996746. eCollection 2022. Front Immunol. 2022. PMID: 36211376 Free PMC article.
Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance.
Bührer ED, Amrein MA, Forster S, Isringhausen S, Schürch CM, Bhate SS, Brodie T, Zindel J, Stroka D, Sayed MA, Nombela-Arrieta C, Radpour R, Riether C, Ochsenbein AF. Bührer ED, et al. Among authors: ochsenbein af. Leukemia. 2022 Nov;36(11):2634-2646. doi: 10.1038/s41375-022-01682-2. Epub 2022 Sep 26. Leukemia. 2022. PMID: 36163264 Free PMC article.
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.
Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Rothschild SI, et al. Among authors: ochsenbein af. J Clin Oncol. 2021 Sep 10;39(26):2872-2880. doi: 10.1200/JCO.21.00276. Epub 2021 Jul 12. J Clin Oncol. 2021. PMID: 34251873 Free article. Clinical Trial.
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study.
Amrein MA, Bührer ED, Amrein ML, Li Q, Rothschild S, Riether C, Jaggi R, Savic-Prince S, Bubendorf L, Gautschi O, Ochsenbein AF. Amrein MA, et al. Among authors: ochsenbein af. Cancer Immunol Immunother. 2021 Feb;70(2):405-415. doi: 10.1007/s00262-020-02688-4. Epub 2020 Aug 7. Cancer Immunol Immunother. 2021. PMID: 32767058 Free PMC article.
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C, Pabst T, Höpner S, Bacher U, Hinterbrandner M, Banz Y, Müller R, Manz MG, Gharib WH, Francisco D, Bruggmann R, van Rompaey L, Moshir M, Delahaye T, Gandini D, Erzeel E, Hultberg A, Fung S, de Haard H, Leupin N, Ochsenbein AF. Riether C, et al. Among authors: ochsenbein af. Nat Med. 2020 Sep;26(9):1459-1467. doi: 10.1038/s41591-020-0910-8. Epub 2020 Jun 29. Nat Med. 2020. PMID: 32601337 Clinical Trial.
TNIK signaling imprints CD8+ T cell memory formation early after priming.
Jaeger-Ruckstuhl CA, Hinterbrandner M, Höpner S, Correnti CE, Lüthi U, Friedli O, Freigang S, Al Sayed MF, Bührer ED, Amrein MA, Schürch CM, Radpour R, Riether C, Ochsenbein AF. Jaeger-Ruckstuhl CA, et al. Among authors: ochsenbein af. Nat Commun. 2020 Apr 2;11(1):1632. doi: 10.1038/s41467-020-15413-7. Nat Commun. 2020. PMID: 32242021 Free PMC article.
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).
Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Früh M, et al. Among authors: ochsenbein af. J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26. J Thorac Oncol. 2019. PMID: 30267838 Free article.
mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer.
Liang SQ, Bührer ED, Berezowska S, Marti TM, Xu D, Froment L, Yang H, Hall SRR, Vassella E, Yang Z, Kocher GJ, Amrein MA, Riether C, Ochsenbein AF, Schmid RA, Peng RW. Liang SQ, et al. Among authors: ochsenbein af. Oncogene. 2019 Jan;38(5):622-636. doi: 10.1038/s41388-018-0479-6. Epub 2018 Aug 31. Oncogene. 2019. PMID: 30171261
T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
Hilmenyuk T, Ruckstuhl CA, Hayoz M, Berchtold C, Nuoffer JM, Solanki S, Keun HC, Beavis PA, Riether C, Ochsenbein AF. Hilmenyuk T, et al. Among authors: ochsenbein af. Oncoimmunology. 2017 Sep 21;7(1):e1365997. doi: 10.1080/2162402X.2017.1365997. eCollection 2017. Oncoimmunology. 2017. PMID: 29296517 Free PMC article.
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Gautschi O, et al. Among authors: ochsenbein af. Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23. Clin Lung Cancer. 2017. PMID: 27993482 Clinical Trial.
TREM-1 links dyslipidemia to inflammation and lipid deposition in atherosclerosis.
Zysset D, Weber B, Rihs S, Brasseit J, Freigang S, Riether C, Banz Y, Cerwenka A, Simillion C, Marques-Vidal P, Ochsenbein AF, Saurer L, Mueller C. Zysset D, et al. Among authors: ochsenbein af. Nat Commun. 2016 Oct 20;7:13151. doi: 10.1038/ncomms13151. Nat Commun. 2016. PMID: 27762264 Free PMC article.
IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms.
Mager LF, Riether C, Schürch CM, Banz Y, Wasmer MH, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, Nakae S, Baerlocher GM, Manz MG, McCoy KD, Macpherson AJ, Ochsenbein AF, Beutler B, Krebs P. Mager LF, et al. Among authors: ochsenbein af. J Clin Invest. 2015 Jul 1;125(7):2579-91. doi: 10.1172/JCI77347. Epub 2015 May 26. J Clin Invest. 2015. PMID: 26011644 Free PMC article.
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research. Gautschi O, et al. Among authors: ochsenbein af. Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5. Clin Lung Cancer. 2015. PMID: 25843489 Clinical Trial.
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Lennerz V, et al. Among authors: ochsenbein af. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2. Cancer Immunol Immunother. 2014. PMID: 24487961 Free PMC article. Clinical Trial.
Dendritic cell-based immunotherapy for myeloid leukemias.
Schürch CM, Riether C, Ochsenbein AF. Schürch CM, et al. Among authors: ochsenbein af. Front Immunol. 2013 Dec 31;4:496. doi: 10.3389/fimmu.2013.00496. Front Immunol. 2013. PMID: 24427158 Free PMC article. Review.
Interferons in hematopoiesis and leukemia.
Schürch CM, Riether C, Ochsenbein AF. Schürch CM, et al. Among authors: ochsenbein af. Oncoimmunology. 2013 Jun 1;2(6):e24572. doi: 10.4161/onci.24572. Epub 2013 Apr 16. Oncoimmunology. 2013. PMID: 23894719 Free PMC article.
From "magic bullets" to specific cancer immunotherapy.
Riether C, Schürch C, Ochsenbein AF. Riether C, et al. Among authors: ochsenbein af. Swiss Med Wkly. 2013 Jan 23;143:w13734. doi: 10.4414/smw.2013.13734. eCollection 2013. Swiss Med Wkly. 2013. PMID: 23348718 Free article. Review.
Modulating CD27 signaling to treat cancer.
Riether C, Schürch C, Ochsenbein AF. Riether C, et al. Among authors: ochsenbein af. Oncoimmunology. 2012 Dec 1;1(9):1604-1606. doi: 10.4161/onci.21425. Oncoimmunology. 2012. PMID: 23264908 Free PMC article.
Destruction of lymphoid organ architecture and hepatitis caused by CD4+ T cells.
Matter MS, Hilmenyuk T, Claus C, Marone R, Schürch C, Tinguely M, Terracciano L, Luther SA, Ochsenbein AF. Matter MS, et al. Among authors: ochsenbein af. PLoS One. 2011;6(9):e24772. doi: 10.1371/journal.pone.0024772. Epub 2011 Sep 23. PLoS One. 2011. PMID: 21966366 Free PMC article.
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M. Stupp R, et al. Among authors: ochsenbein af. J Clin Oncol. 2010 Jun 1;28(16):2712-8. doi: 10.1200/JCO.2009.26.6650. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439646 Free article. Clinical Trial.
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, Broek Mv, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD. Flatz L, et al. Among authors: ochsenbein af. Nat Med. 2010 Mar;16(3):339-45. doi: 10.1038/nm.2104. Epub 2010 Feb 7. Nat Med. 2010. PMID: 20139992 Free PMC article.
Decreased tumor surveillance after adoptive T-cell therapy.
Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, von Laer D, Ochsenbein AF. Matter M, et al. Among authors: ochsenbein af. Cancer Res. 2007 Aug 1;67(15):7467-76. doi: 10.1158/0008-5472.CAN-06-4372. Cancer Res. 2007. PMID: 17671217
Elimination of chronic viral infection by blocking CD27 signaling.
Matter M, Odermatt B, Yagita H, Nuoffer JM, Ochsenbein AF. Matter M, et al. Among authors: ochsenbein af. J Exp Med. 2006 Sep 4;203(9):2145-55. doi: 10.1084/jem.20060651. Epub 2006 Aug 21. J Exp Med. 2006. PMID: 16923852 Free PMC article.
Immunological ignorance of solid tumors.
Ochsenbein AF. Ochsenbein AF. Springer Semin Immunopathol. 2005 Jun;27(1):19-35. doi: 10.1007/s00281-004-0192-0. Epub 2005 Jan 27. Springer Semin Immunopathol. 2005. PMID: 15965711 Review.
Neutralizing antiviral antibody responses.
Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, Fehr T, Bachmann MF, Kalinke U, Hengartner H. Zinkernagel RM, et al. Among authors: ochsenbein af. Adv Immunol. 2001;79:1-53. doi: 10.1016/s0065-2776(01)79001-3. Adv Immunol. 2001. PMID: 11680006 Free PMC article. Review.
IgD can largely substitute for loss of IgM function in B cells.
Lutz C, Ledermann B, Kosco-Vilbois MH, Ochsenbein AF, Zinkernagel RM, Köhler G, Brombacher F. Lutz C, et al. Among authors: ochsenbein af. Nature. 1998 Jun 25;393(6687):797-801. doi: 10.1038/31716. Nature. 1998. PMID: 9655395